Search results
Showing 1 to 15 of 35 results for azathioprine
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: 24 July 2024
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]
In development [GID-TA11349] Expected publication date: TBC
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Immunosuppressive therapy for kidney transplant in adults (TA481)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.